Cardiff Lexington Corporation

AI-generated fair value estimate for this company.

Method: Levered equity-residual DCF: FY2025 revenue base $11.5M; growth 30%/25%/20% years 1-3, 15%/12%/10% years 4-6, 8%/6%/5%/4% years 7-10; EBITDA margin ramps 5% to 15% over 10 years; less capex (3% of revenue) and working-capital build (5% of revenue growth); 18% discount rate; 3% terminal growth, giving Enterprise Value ~$14.7M. Net debt ~$23.9M (line of credit $18.9M, converts $1.1M, other liabilities, less minimal cash) exceeds EV; ~17.0M shares outstanding.

Reasoning: Cardiff Lexington is a highly levered, going-concern-flagged healthcare roll-up with growing revenue but total liabilities that dwarf its market cap, so an EV-minus-net-debt DCF is needed to show nearly all enterprise value currently accrues to debtholders, leaving equity as a thin residual.